Physical state and viral load as predictive biomarkers for persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study by Manawapat, Anna et al.
  
Introduction 
 
The observation that a persistent infection with 
high risk (hr) human papillomavirus (HPV) types 
is a necessary cause of cervical cancer [1] of-
fers not only the prospect of an effective pri-
mary prevention, but also the possibility of test-
ing for hrHPV types to improve the efficiency of 
cervical cancer screening programmes. The 
continued presence of hrHPV DNA for ≥ 24 
months identifies women at particular risk for 
cervical intraepithelial neoplasia of grade 3 or 
higher (CIN3+) [2]. In contrast, a negative HPV 
result has been shown to be associated with a 
greater long-term protection from CIN3 com-
pared with a normal cytology result [3-5]. HPV16 
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Abstract: Persistent infection with a high risk (hr) human papillomavirus (HPV) has been established as the main 
cause of cervical cancer and high-grade cervical intraepithelial neoplasia (CIN3). Because most infections are tran-
sient, testing for hrHPV lacks specificity and has a low positive predictive value. It has been suggested that additional 
parameters like viral load and physical status of the viral genome could improve the effectiveness of HPV-based 
screening. We investigated the association between HPV16 viral load and physical state with viral persistence or risk 
of incident CIN3 or worse in a population-based prospective cohort study comprising 8656 women (20-29 years). All 
participants had two gynecological examinations two years apart and were followed through the nationwide Danish 
Pathology Data Bank (median follow-up: 12.9 yrs). Seventynine cervical swabs from women with a persistent HPV16 
infection were available for analysis. For comparison we selected a random age-matched sample of transiently 
HPV16 infected women (N=91). Persistently infected women with incident CIN3 or cancer (CIN3+; N=31) were com-
pared to women with normal cytology during follow up (non-progressors; N=39). Quantitative real-time PCR for 
HPV16E6, E2 and IFNb1 was done to determine the HPV16 viral load and the E2/E6 ratio was used as a surrogate 
marker for integration. Women with normal cytology who became persistently HPV16 infected had a significantly 
lower HPV16 load at baseline than women who cleared the infection (median 4.72 copies/cell versus median 20.0 
copies/cell, respectively; p=0.0003). There was no difference in viral load at enrollment between women who pro-
gressed to CIN3+ and women who stayed cytologically normal (p=0.85). At the second examination viral load tended 
to be higher in women who progressed, but the difference was not statistically significant (p=0.39). The E2/E6 ratio 
was shown to be lower in the persistently infected group (p<0.0001) already at the first examination, but no differ-
ence between non-progressors and CIN3+ cases was observed at any of the two examinations (p=0.61 and 0.86). 
Lower viral load and integration of the viral genome are predictive for the persistence of HPV16 DNA, but not for the 
progression of a persistent HPV16 infection to CIN3+ in women with normal cytology.  
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is the most common carcinogenic type in pre-
invasive and cervical cancer and is detectable 
in roughly 50% of women with CIN3+ [6, 7]. It 
was shown to cause persistent infections in 
30% of the women [8, 9]. 
 
The inability of a single hrHPV DNA test to dis-
criminate between persistent and transient in-
fections urges the need for additional parame-
ters that enable the identification of hrHPV-
positive women who are indeed at risk of 
CIN3+. In this context, several studies have in-
vestigated the value of viral DNA load or the 
integration status of the viral DNA as risk deter-
minants for high-grade CIN. While some case 
control studies found no association of viral 
load with disease status [10, 11] others re-
ported higher load in CIN2+ cases [12-16]. In 
one study this was only due to the inclusion of 
invasive squamous cervical cancer in the case 
group [17]. Studies with a prospective design 
reported higher viral load to be associated with 
a modest increase in the incidence of cytologi-
cal abnormalities [18] and to be predictive for 
incident CIN2/3+, but restricted these observa-
tions only to cases of infections with HPV16 [19, 
20] or HPV16, 31 and 33 [21]. 
 
The physical state of the viral genome was al-
most exclusively investigated in case control 
studies and the majority reported an associa-
tion between integration and increasing severity 
of the lesions [11, 22-25]. However, it has to be 
noted that integrated viral DNA was already 
found in up to 44% of control samples with nor-
mal cytology [17, 26] which does not support 
the use of this parameter as a biomarker. These 
early integration events were rather frequently 
observed for HPV16 (26%) and HPV18 (58%) 
already in young women soon after sexual debut 
[27].  
 
Integration of the viral DNA usually disrupts the 
E2 gene and causes the lack of the E2 repres-
sor protein or the more potent E8^2C repressor 
[28, 29], which leads to subsequent overexpres-
sion of the viral oncogenes E6 and E7. However, 
frequently mixed levels of episomal and inte-
grated forms have been described especially in 
normal and mildly abnormal epithelium. Purely 
integrated forms were found enriched in CIN3+, 
where the extinction of episomal forms and 
thereby the exclusion of trans-repression of the 
integrated genomes by the E2/E8^E2C repres-
sor proteins provides the infected cell with a 
clear growth advantage.  
 
Therefore studies are required that combine a 
robust measurement of viral load of the most 
relevant hrHPV types in conjunction with the 
physical state of the viral genome in the frame 
of a prospective cohort study. 
 
In this study, we measured E2, E6 and IFNb1 
mRNA levels using quantitative real-time PCR 
(qPCR) in HPV16 positive cervical samples from 
a large population-based prospective cohort [2]. 
The aim of our work was to evaluate viral load 
and physical state as potential predictive bio-
markers to assess the risk for persistence and 
the risk for progression in persistently infected 
women. 
 
Materials and methods 
 
The Danish HPV cohort 
 
The present paper is based on women (20-29 
years of age at enrollment) participating in a 
Danish prospective cohort study. The data col-
lection procedures have previously been de-
scribed in detail [2]. In brief, the women were 
selected at random from the general female 
population of Copenhagen, Denmark where 
every citizen has a unique 10-digit personal 
identification number, which is universally used 
in all health registries. These identification num-
bers, which contain information on sex and date 
of birth, are registered in the computerized Dan-
ish Central Population Register, which includes 
information on vital status, emigration and cur-
rent address. Between May 15, 1991 and Janu-
ary 31, 1993, 11088 women were enrolled in 
the study for the first gynaecological examina-
tion (Figure 1). Before entering the study, all 
participants were informed verbally and in writ-
ing about the study and all participants signed a 
written informed consent. The study was ap-
proved by the national Scientific Ethical Commit-
tee and the national Data Protection Board. 
 
Approximately 2 years after enrollment (from 
October 1, 1993 to January 31, 1995), the 
study participants were re-invited, in the same 
order in which they were originally enrolled, for 
a second gynecological examination. A total of  
8656 women (78%) participated in this second 
examination. At both gynaecological examina-
tions, a Pap smear was obtained, and a cervical 
swab containing ecto- and endocervical cells 
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was taken and placed in a tube containing 
phosphate-buffered saline and stored at -80°C 
for subsequent HPV DNA testing.  
 
After the second examination the cohort was 
followed passively through the Pathology Data 
Bank which is a nationwide pathology register 
that contains information on all cervical cytology 
examinations and all cervical biopsy specimens, 
cones and hysterectomies performed in Den-
mark in the last 20 years. Clinical communica-
tion between pathology departments and the 
Pathology Data Bank is ensured through an 
online real-time data reporting system. Abnor-
mal cervical diagnoses are usually reported as 
atypia/koilocytosis, mild dysplasia, moderate 
dysplasia, severe dysplasia, or carcinoma in 
situ. The histological diagnoses were translated 
into CIN nomenclature as follows: atypia/
koilocytosis and mild dysplasia were grouped as 
CIN1, moderate dysplasia was categorized as 
CIN2 and severe dysplasia and carcinoma in 
situ were categorized as CIN3.  
 
The existence of the nationwide Central Popula-
tion Register and the unique personal identifica-
tion numbers ensures correct linkages between 
registries and makes it possible to conduct fol-
low-up studies with virtually no loss of follow-up.  
 
Using the personal identification number for 
each woman, the study cohort was linked to the 
Pathology Data Bank and followed until March 
6, 2007 to identify all cervical pathological le-
sions and diagnostic or treatment procedures. 
As HPV DNA testing took place several years 
after the study examinations were performed, 
the women were unaware of the results ob-
tained in the study, and results of the HPV DNA 
testing were not used for referrals or clinical 
management of the women. 
 
All women in the cohort were tested at both ex-
aminations for the presence of hrHPV DNA by 
the Hybrid Capture 2 test (HC2, Qiagen, Hilden, 
Germany) using the high risk probe cocktail and 
samples positive in the HC2 high risk probe 
were genotyped using the LiPav2 reverse line 
blot test system (Innogenetics) [30-32]. 
 
The study population (Figure 1) for the analyses 
presented here comprises women who partici-
pated in both examinations (N=8656). We ex-
cluded a total of 977 women who participated 
in the second examination only through a tele-
phone interview, had abnormal smear at the 
first or the second examination or had no cervi-
cal swab (e.g. due to menstruation at the time 
of examination or a cervical swab that was in-
adequate for HPV testing). In addition, we ex-
cluded 197 women with no follow-up examina-
tion after the second examination, leaving 7482 
women. A total of 296 women were HPV16 posi-
tive at the first examination and of these, 84 
women were also HPV16 positive at the second 
examination (defined as persistent HPV16 infec-
tion). Five women were excluded due to insuffi-
cient material for further analysis leaving 79 
women. Among the women who were HPV16 
positive at the first examination and became 
HPV16 negative at the second examination 
(transient HPV16 infection), we randomly se-
lected 91 women so that the age distribution 
was similar to that of the HPV16 persistors. 
Among the 79 women with persistent HPV16 
infection, a total of 40 women developed abnor-
mal cytology during follow-up. The correspond-
ing histological diagnoses comprised CIN1 
(N=4), CIN2 (N=5), CIN3 (N=29) and cervical 
cancer (N=2). This study focused on CIN3 or 
worse, so in the analysis of risk of progression 
among women with a persistent HPV16 infec-
tion we included 31 women with incident CIN3 
or cancer (CIN3+), and 39 women with normal 
cytology during follow-up.  
 
DNA extraction and qPCR 
 
DNA was extracted from residual material from 
the HC2 assay using a Magna Pure device 
(Roche Molecular Systems, Pleasanton, CA). 
Quantification of the human IFNB1 gene, the 
HPV16 E6 and E2 genes was performed with a 
Light Cycler 480 (Roche Applied Science, Mann-
heim, Germany). A predesigned primer pair 
(QT00203763, Qiagen, Hilden, Germany) was 
used for detection of IFNB1. The HPV16 E2 and 
E6 primers have been previously described 
[33]. PCR was performed in a final volume of 20 
µl containing 1× Light Cycler 480 SYBR green I 
Master Mix (Roche Diagnostics, Mannheim, Ger-
many), 0.3 µM primer and 5 µl of DNA. The am-
plification conditions were 10 min at 95°C, and 
then 10 sec at 95°C, 15 sec at 55°C, 15 sec at 
72°C for 45 cycles. Amplification products were 
analysed by melting curves with a thermal pro-
file of 10 sec at 95°C, 30 sec at 60°C followed 
by heating to 90°C. 
 
Amplification of the single-copy IFNB1 gene was 
used to correct HPV copy numbers for the 
amount of cells in the cervical swab material. A 
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standard curve for IFNB1 was generated using 
serial dilutions of total genomic DNA isolated 
from cultured normal human keratinocytes 
(NHK). Cell numbers were calculated assuming 
a DNA content of 6.6pg per human diploid cell. 
Standard curves used to quantify the copy num-
bers of the E2 and the E6 genes of HPV16 were 
generated using 107, 106, 105, 104, 103, 102 
and 101 copies of a cloned HPV16 genome as 
previously described [33]. Copy numbers in 
samples were calculated using the Light Cycler 
480 software version 1.5.0 second-derivative 
maximum algorithm. All qPCR reactions were 
run in duplicate showing extremely high concor-
dance and values were then averaged for analy-
sis. In each run non-template controls and posi-
tive controls were included.  
 
Viral load and physical state determination 
 
HPV16 copy numbers per cell were calculated 
by dividing E6 copies by the cell numbers calcu-
lated from the IFNB1 amplifications. 
 
The physical state of HPV16 was determined 
using real-time PCR targeting the E6 and E2 
open reading frame of HPV16, because the E2 
gene is often lost during viral integration [34]. 
Thus, E2 and E6 gene segments are present in 
equivalent amounts in episomal HPV genomes, 
whereas integrated HPV genomes would have 
E6 present and the E2 gene absent. Assignment 
of integrated, mixed or episomal physical state 
was calculated as described elsewhere [35]. 
Integration was defined as an E2/E6 ratio be-
tween zero and 0.15 [36]. An E2/E6 ratio be-
tween 0.15 and 0.9 indicates the presence of 
both integrated and episomal forms and ratios 
of greater than 0.9 indicated the predominance 
of episomal forms [12]. However, it has to be 
taken into account that tandem integrated head
-to-tail viral genomes would also result in values 
≥ 0.9 falsely indicating episomal genomes. We 
therefore concentrated only on the reliable cut-
Figure 1. Overview of the study design and the cohort. Out of 7 482 eligible women 79 women were persistently in-
fected with HPV16. Among the women who had a negative HPV test at the second examination (transient infections), 
we randomly selected 91 age matched women as controls. In the persistently infected group 39 women showed no 
progression within the median follow-up time of 12.9 years. Among the women eligible for analysis 4 developed CIN1, 
5 developed CIN2 and 31 progressed to CIN3 or cancer.  
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off ≤ 0.15 as a surrogate marker for integration. 
 
Statistical analysis 
 
In the analysis of viral load and physical state as 
risk factors for persistence, we compared tran-
siently HPV16 infected women with persistently 
HPV16 infected women using cervical samples 
taken at the first examination.  
 
We also assessed the importance of viral load 
and physical state for progression within the 
group of persistently HPV16 infected women. 
For analysis of those with incident CIN3+ versus 
those who stayed cytologically normal during 
follow-up we investigated samples both from 
the first and the second examination, sepa-
rately. The Mann-Whitney test was used to test 
for significant differences. P values were consid-
ered significant if less than 0.05. Receiver oper-
ating characteristics (ROC) curves were calcu-
lated using GraphPad Prism 5 ® (GraphPad Soft-
ware, San Diego). 
 
Results 
 
Viral loads in cervical swabs taken at the first 
examination from women infected with HPV16 
ranged from <1 to 2010 viral DNA copies per 
cell (c/c) (median: 20.0) in women who cleared 
the infection till the second examination 
(transient infections) and from <1 to 1958 viral 
DNA c/c (median: 4.72) in women who were 
HPV16 positive at both examinations (persistent 
infections; Table 1). The median viral load at the 
first examination was significantly higher in 
women with a transient HPV16-infection versus 
women that developed a persistent infection 
(p=0.0003; Figure 2A), although a wide range 
was observed within both groups.  
 
To investigate whether viral load could be pre-
dictive for the development of incident CIN3+, 
we compared persistently infected women who 
stayed cytologically normal (non-progressors; 
N=39) to those women who developed CIN3+ 
after the second examination during the follow 
up time (N=31). The measurements of viral load 
in samples taken from non-progressor women 
at the first examination ranged from <1 to 225 
viral DNA c/c (median: 3.7) and in those who 
developed CIN3+ from <1 to 171 c/c (median: 
3.96; Table 2). No significant difference in the 
median viral load between non-progressors and 
women that progressed to CIN3+ was observed 
(p=0.85; Figure 2B). 
 
When we repeated the experiment with samples 
from the second examination, we observed a 
viral load ranging in non-progressors from 1 to 
745 viral DNA c/c (median: 13.93) and in 
women who developed CIN3+ from <1 to 464 
c/c (median: 19.81; Table 2). This difference 
was, however, not statistically significant 
(p=0.39; Figure 2C).  
 
The analysis of the E2/E6 ratio of HPV16, as a 
proxy for physical status, showed values ranging 
from zero to 1.24 (median: 0.68) in samples 
taken at the first examination from women with 
transient infections, while the values of the E2/
E6 ratio were significantly lower (p<0.0001; 
Figure 3A) in persistently infected women 
(median: 0.53, range: 0-0.83; Table 3). 
 
To investigate whether the E2/E6 ratio could be 
a predictive marker for the development of 
CIN3+ we compared women with persistent 
HPV16 infection who stayed cytologically normal 
with those who developed CIN3+ during follow 
up. In samples taken at the first examination 
the E2/E6 ratio in non-progressor women 
ranged from 0.1 to 0.82 (median: 0.52) and in 
women with persistent infections who devel-
oped incident CIN3+ from 0.1 to 0.83 (median: 
0.48; Table 4). No significant correlation be-
tween the E2/E6 ratio as a proxy for physical 
state of the viral genome and progression to 
CIN3+ was found (p=0.61; Figure 3B).  
 
Repeating the analysis using samples from the 
second examination showed E2/E6 ratios in 
non-progressors from 0.06 to 0.55 (median: 
0.20) and in women with persistent infections 
who developed CIN3+ from 0.07 to 0.6 
(median: 0.19; Table 4). Again no significant 
correlation between E2/E6 ratio and progres-
sion to CIN3+ was found (p=0.86; Figure 3C).  
Table 1. Comparison of viral load in women 
who cleared an HPV16 infection (transient in-
fection) and women with persistent HPV16 
infection 
Viral load in     
Samples taken at Transience Persistence 
  (N=91) (N=79) 
First examination:     
Median (copies/cell) 20 4.72 
25-75% quartile 4.5-65.8 1.8-21.36 
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Interestingly an analysis of the E2/E6 ratio com-
bined with the viral load quantification in sam-
ples from persistently infected women compar-
ing the first and the second examination time 
point confirmed an increase of integrated ge-
nomes (E2/E6 ratio <0.15) over time. In addi-
tion a trend to lower E2/E6 ratios was visible 
when comparing samples from the first exami-
nation to samples from the second. While the 
E2/E6 ratio of HPV16 at the first examination 
ranged from 0-0.83 (median 0.53) with only 
7.6% integrated genomes and 92.4% samples 
had a mix of integrated and probably episomal 
genomes (Figure 4) we observed at the second 
examination an E2/E6 ratio from 0.06 to 0.6 
(median: 0.21) with 21.5% integrated genomes 
and only 78.4% mixed forms.  
 
When we performed receiver operating charac-
teristic (ROC) curve analysis in order to analyze 
the utility of viral load or physical state meas-
Table 2. Comparison of viral load in women 
staying cytologically normal (non-progressors) 
and women developing CIN3 or worse 
(progressors) 
Viral load in     
samples taken at No progression CIN3+ 
  (N=39) (N=31) 
First examination:     
Median (copies/cell) 3.7 3.96 
25-75% quartile 1.8-14.61 1.27-38.5 
Second examination:     
Median (copies/cell) 13.93 19.81 
25-75% quartile 3.28-52.11 3.96-74.61 
Figure 2. HPV16 viral load in persistent versus transient infections. Viral load values are shown on the Y-axis in HPV 
copies per cell (c/c) and are log transformed. The upper and lower boundaries of the boxes represent the 75th and 
25th percentiles, respectively. The black line within the box represents the median; the whiskers represent the mini-
mum and maximum values. A. Log10 HPV16 DNA loads were compared between women with transient infections 
(n=91) and persistent infections (N=79). A significant difference between transiently (median 20c/c; 25-75% quar-
tiles of 4.5-65.8) and persistently (median: 4.72/c; 25-75% quartiles of 1.8-21.36) infected women (p=0.0003) was 
observed. B. HPV16 DNA loads were compared between samples taken at the first examination from persistently 
infected women who did (N=31) or did not (N=39) progress to CIN3+. No difference (p=0.85) between non-
progressors (median 3.7c/c; 25-75% quartiles of 1.8-14.61) and progressors (median: 3.96c/c; 25-75% quartiles of 
1.27-38.5) was observed. C. Log10 HPV16 DNA loads were compared between samples taken at the second exami-
nation from persistently infected women who did (N=31) or did not (N=39) progress to CIN3+. A non significant differ-
ence (p=0.39) between non-progressors (median 13.93c/c; 25-75% quartiles of 3.28-52.11) and progressors 
(median: 19.81c/c; 25-75% quartiles of 3.96-74.61) was observed. 
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urements for diagnostic purposes predicting 
clearance or persistence of HPV16 infections 
we obtained comparable values for viral load 
(p=0.00028, AUC=0.662) and physical state 
(p<0.0001, AUC=0.6968; data not shown).  
Similarly, a ROC curve analysis for the viral load 
and E2/E6 ratio predicting progression to CIN3+ 
showed that neither viral load (first examination: 
p=0.84, AUC=0.514; second examination: 
p=0.388, AUC=0.56) nor physical state (first 
Figure 3. HPV16 physical status in persistent versus tran-
sient infections. E2/E6 ratios are shown on the Y-axis. 
The upper and lower boundaries of the boxes represent 
the 75th and 25th percentiles, respectively. The black line 
within the box represents the median; the whiskers repre-
sent the minimum and maximum values. A. E2/E6 ratios 
were compared between women with transient infections 
(N=91) and persistent infections (N=79). A significant 
difference (p<0.0001) between transiently (median 0.68; 
25-75% quartiles of 0.46-0.80) and persistently (median: 
0.53; 25-75% quartiles of 0.42-0.61) infected women 
was observed. Within the group of women with a transient 
infection (N=91) two samples showed a E2/E6 ratio be-
low 0.15, 80 women showed mixed episomal and inte-
grated forms (E2/E6 ratio between 0.15-0.90) and nine 
women had an E2/E6 ratio above 0.9. The group of per-
sistently infected women (N=79) consisted of six women 
with integrated forms (E2/E6>0.15), 73 women showed 
mixed episomal and integrated forms (E2/E6 ratio be-
tween 0.15-0.90) and no women had an E2/E6 ratio 
above 0.9. B. E2/E6 ratios were compared between per-
sistently infected women who did (N=31) or did not 
(N=39) progress to CIN3+ from samples taken at the first 
examination. No significant difference (p=0.61) between 
non-progressors (median 0.52; 25-75% quartiles of 0.4-
0.63) and progressors (median: 0.48; 25-75% quartiles of 
0.34-0.59) was observed. Within the group of women who 
showed no progression (N=39) three samples showed an 
E2/E6 ratio below 0.15, 36 women showed mixed epi-
somal and integrated forms (E2/E6 ratio between 0.15-
0.90) and no woman had an E2/E6 ratio above 0.9. The 
group of women with CIN3+ (N=31) consisted of three 
women with integrated forms (E2/E6>0.15), 28 women 
showed mixed episomal and integrated forms (E2/E6 
ratio between 0.15-0.90) and no woman had an E2/E6 
ratio above 0.9. C. E2/E6 ratios were compared between 
persistently infected women who did (N=31) or did not 
(N=39) progress to CIN3+ from samples taken at the 
second examination. No significant difference (p=0.86) 
between non-progressors (median 0.2; 25-75% quartiles 
of 0.17-0.30) and progressors (median: 0.19; 25-75% 
quartiles of 0.14-0.28) was observed. Within the group of 
non-progressors (N=39) eight samples had integrated 
genomes (E2/E6 ratio below 0.15) and 31 women 
showed mixed episomal and integrated forms (E2/E6 
ratio between 0.15-0.90). The group of women with 
CIN3+ (N=31) consisted of eight women with integrated 
forms (E2/E6>0.15), 23 women showed mixed episomal 
and integrated forms (E2/E6 ratio between 0.15-0.90) 
and no woman had an E2/E6 ratio above 0.9. 
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examination: p=0.607, AUC=0.536; second 
examination: p=0.855, AUC=0.513) enabled 
discrimination between development of CIN3+ 
or not (data not shown). 
 
Discussion 
 
To measure viral load and the physical status of 
the genome we used quantitative real time PCR 
for the E6 and E2 genes of HPV16 and normal-
ized the values to the cell number in each sam-
ple through additional measurement of the sin-
gle copy gene IFNB1. This method is superior to 
semi-quantitative measurement of viral load by 
using e.g. the RLU/CO values of HC2, where the 
cell number of the analyzed sample is unknown 
and multiple infections can cause a viral load 
that is not attributable to a distinct HPV type or 
to dot blot analysis using estimated signal 
strength [37]. 
 
We find that HPV16 positive women who de-
velop a persistent infection have a significantly 
lower median viral load (p=0.0003) at the first 
examination in comparison to women that are 
able to clear the infection. Interestingly a ROC 
curve analysis provided some evidence that 
indeed using low viral load could be possibly 
used as a diagnostic parameter. Moreover if 
HPV testing and genotyping would be combined 
with viral load measurement this may help to 
identify women with greatest risk for cervical 
cancer as persistence of infection is a major 
risk factor besides the prevailing HPV type [2]. 
The group of women with lower viral load al-
ready may have integrated viral genomes in 
their infected cells that do not support virus 
replication any longer. We observed integrated, 
a mixture of integrated and episomal forms and 
potentially episomal DNA in respectively 3.3%, 
86.81% and 9.89% of the samples from the 91 
women who cleared the infection. Samples from 
women who developed a persistent infection 
showed in contrast 7.59% integrated and 
92.41% mixed HPV16 genomes and no epi-
somal DNA. Our data confirm that integration 
can be an early event, because a high number 
of samples with normal cytology harboured al-
ready integrated HPV16 genomes. Those 
women with integrated genomes might have a 
higher risk of becoming persistently infected as 
fewer viral epitopes derived from E1 and espe-
cially E2 [38] are presented to the immune sys-
tem compared to cells with episomal and poten-
tially productive infections and therefore may be 
less likely eliminated by cell mediated immunity. 
In most cells with integrated HPV only the trans-
forming genes E6/E7 are expressed and re-
quired for the transformed state. The expres-
sion of the viral oncogenes indeed seems to be 
tolerated by the immune system of some 
women as it has been shown earlier that the 
lack of response to E6 by cell mediated immu-
nity is important in the persistence of an HPV16 
infection [39]. 
 
The substantial overlap of the viral load meas-
urements between women that cleared versus 
those that with persistent infections, however, 
Table 4. Comparison of E2/E6 ratio in women 
staying cytologically normal (non-progressors) 
and women developing CIN3 or worse 
(progressors) 
    
No progression CIN3+ 
 (N=39) (N=31) 
First examination:   
  
Median (copies/cell) 0.52 0.48 
25-75% quartile 0.4-0.63 0.34-0.59 
Integrated <0.15 3 3 
Mixed 0.15-0.90 36 28 
Episomal >0.9 0 0 
Second examination:     
Median (copies/cell) 0.2 0.19 
25-75% quartile 0.17-0.3 0.14-0.28 
Integrated <0.15 8 8 
Mixed 0.15-0.90 31 23 
Episomal >0.9 0 0 
E2/E6 ratio in samples 
taken at 
Table 3. Comparison of E2/E6 ratio in women 
who cleared an HPV16 infection (transient 
infection) and women with persistent HPV16 
infection 
E2/E6 ratio in     
Samples taken at Transience Persistence 
  (N=91) (N=79) 
First examination:     
Median (copies/cell) 0.68 0.53 
25-75% quartile 0.46-0.8 0.42-0.61 
Integrated <0.15 2 6 
Mixed 0.15-0.90 80 73 
Episomal >0.9 9 0 
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makes it difficult to determine cut-off values for 
risk prediction.  
 
In the present study we did not observe a signifi-
cant difference in the median levels of viral load 
between women persistently infected with 
HPV16 who developed a CIN3+ or not during 
follow up. This is in line with some studies that 
found no association of higher viral load with 
cases, although others reported such an asso-
ciation [13, 40-42]. It has to be noted that we 
only genotyped women that were positive in the 
HC2 test using the high risk probe since women 
that test negative by the HC2 test high risk 
probe have virtually no risk of developing CIN3+ 
within 6 years of follow up [5]. Other studies 
that used more sensitive detection methods 
with no clinically validated cut-off might find 
stronger associations between higher viral load 
and high grade disease [12, 14-16]. In addition 
it is possible that at the second examination 
women already had cervical lesions that were 
not detected by cytology, as the average sensi-
tivity of a single cytology screen is not exceeding 
50% for detection of a HSIL lesion [43]. 
 
When we measured the E2/E6 ratio as a surro-
gate marker for the physical status of the viral 
genome we considered only ratios ≤ 0.15 as a 
reliable indicator for the presence of integrated 
genome copies as ratios above 0.9 might be 
indicative for an episomal state, but are not 
excluding the presence of integrated head to 
tail tandem genome copies. We observed that 
Figure 4. Correlation of 
HPV16 viral load and physi-
cal status from persistently 
HPV16 infected women 
(N=79). HPV16 viral loads 
are displayed on the y-axis 
in copies/cells (c/c). The 
corresponding E2/E6 ratios 
are plotted on the x-axis. In 
contrast to samples taken 
at the first examination with 
only six samples with inte-
grated genomes, samples 
taken at the next examina-
tion two years later revealed 
a higher number of samples 
with integrated HPV16 ge-
nomes (N=17). 
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women that became persistently infected had a 
significantly lower median E2/E6 ratio (higher 
integration rate) in comparison to women that 
were able to clear the infection. A ROC curve 
analysis supported this finding showing that 
using an E2/E6 ratio of ≤ 0.15 could possibly be 
used as diagnostic parameter with a sensitivity 
of approximately 91%, but at the cost of a speci-
ficity as low as 48% (data not shown). One pos-
sible explanation for the low specificity of the 
E2/E6 ratio are findings by others and by us 
that already in 29%-89% of cytologically normal 
samples integrated viral genome copies could 
be found [11, 17, 35]. The suboptimal perform-
ance of the parameter “E2/E6 ratio” could also 
be due to the fact, that we did not exclude 
women that were infected by other HPV types 
with undefined physical status of the genome in 
addition to HPV16, which finally may have 
caused the CIN3+ lesion. However, when we 
repeated the analysis with just single HPV16 
infections we observed no difference to our ini-
tial observation (data not shown). Again it can 
be hypothesized that cells with predominantly 
integrated viral genome copies are at lower risk 
to be cleared by cell mediated immunity and 
that the loss of the negative regulator E2 and 
especially E8^E2C [29] increases viral onco-
gene expression, which fosters persistence. In 
conclusion a combination of low viral load and 
an E2/E6 ratio of ≤ 0.15 may be a useful 
marker to attach to a single HPV test for the risk 
stratification of women in cervical cancer 
screening. 
 
In contrast to other studies with a case control 
design we could not find a significant difference 
in the E2/E6 ratio between cases (women that 
developed CIN3+ during prospective follow up) 
and non-progressors. That was true for samples 
taken at the first and at the second phase. 
When we, however, plotted the viral load 
against E2/E6 ratio for the persistent cases and 
compared the results for the first versus the 
second examination it became obvious that a 
shift towards lower E2/E6 ratios was visible 
over time. This supports earlier findings from us 
[2] that HPV16 has the highest tendency for 
persistence among all hr HPV types, which 
might be due to a high integration rate. 
 
In conclusion our data show that lower viral load 
at baseline and integration of the viral genome 
are predictive for the persistence of HPV16 
DNA, but not for the progression of a persistent 
infection with HPV16 to development of CIN3+ 
during follow up in women with normal cytology 
at baseline.  
 
Acknowledgement 
 
This work was supported by the Mermaid pro-
ject (MERMAID-2), Savværksejer Jeppe Juhl og 
Hustru Ovita Juhls Mindelegat, and the Danish 
Cancer Society.  
 
Address correspondence to: Thomas Iftner, PhD, 
University Hospital Tuebingen, Institute for Medical 
Virology and Epidemiology of Viral Diseases, Division 
of Experimental Virology, Elfriede-Aulhorn-Str. 6 D-
72076 Tuebingen, Germany.Tel: ++49 7071/29-
80246, Fax: ++49 7071/29-5419, E-mail: tho-
mas.iftner@med.uni-tuebingen.de 
 
References 
 
[1] Clifford G, Franceschi S, Diaz M, Munoz N and 
Villa LL. Chapter 3: HPV type-distribution in 
women with and without cervical neoplastic 
diseases. Vaccine 2006; 24 Suppl 3: S3/26-
34. 
[2] Kjaer SK, Frederiksen K, Munk C and Iftner T. 
Long-term absolute risk of cervical intraepithe-
lial neoplasia grade 3 or worse following human 
papillomavirus infection: role of persistence. J 
Natl Cancer Inst 2010; 102: 1478-1488. 
[3] Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, 
van Kemenade FJ, Rozendaal L, Snijders PJ 
and Meijer CJ. High-risk HPV type-specific clear-
ance rates in cervical screening. Br J Cancer 
2007; 96: 1419-1424. 
[4] Cuzick J, Szarewski A, Mesher D, Cadman L, 
Austin J, Perryman K, Ho L, Terry G, Sasieni P, 
Dina R and Soutter WP. Long-term follow-up of 
cervical abnormalities among women screened 
by HPV testing and cytology-Results from the 
Hammersmith study. Int J Cancer 2008; 122: 
2294-2300. 
[5] Dillner J, Rebolj M, Birembaut P, Petry KU, Sza-
rewski A, Munk C, de Sanjose S, Naucler P, 
Lloveras B, Kjaer S, Cuzick J, van Ballegooijen 
M, Clavel C and Iftner T. Long term predictive 
values of cytology and human papillomavirus 
testing in cervical cancer screening: joint Euro-
pean cohort study. BMJ 2008; 337: a1754. 
[6] Bosch FX, Manos MM, Munoz N, Sherman M, 
Jansen AM, Peto J, Schiffman MH, Moreno V, 
Kurman R and Shah KV. Prevalence of human 
papillomavirus in cervical cancer: a worldwide 
perspective. International biological study on 
cervical cancer (IBSCC) Study Group. J Natl 
Cancer Inst 1995; 87: 796-802. 
[7] Herrero R, Hildesheim A, Bratti C, Sherman ME, 
Hutchinson M, Morales J, Balmaceda I, Green-
berg MD, Alfaro M, Burk RD, Wacholder S, 
Biomarkers of HPV16-positive women 
 
 
202                                                                                                            Am J Cancer Res 2012;2(2):192-203 
Plummer M and Schiffman M. Population-
based study of human papillomavirus infection 
and cervical neoplasia in rural Costa Rica. J 
Natl Cancer Inst 2000; 92: 464-474. 
[8] Nielsen A, Kjaer SK, Munk C, Osler M and Iftner 
T. Persistence of high-risk human papillomavi-
rus infection in a population-based cohort of 
Danish women. J Med Virol 2010; 82: 616-
623. 
[9] Schiffman M, Herrero R, Desalle R, Hildesheim 
A, Wacholder S, Rodriguez AC, Bratti MC, 
Sherman ME, Morales J, Guillen D, Alfaro M, 
Hutchinson M, Wright TC, Solomon D, Chen Z, 
Schussler J, Castle PE and Burk RD. The car-
cinogenicity of human papillomavirus types 
reflects viral evolution. Virology 2005; 337: 76-
84. 
[10] Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, 
Lin E, Luthra R and Zhang W. Distribution and 
viral load of eight oncogenic types of human 
papillomavirus (HPV) and HPV 16 integration 
status in cervical intraepithelial neoplasia and 
carcinoma. Mod Pathol 2007; 20: 256-266. 
[11] Briolat J, Dalstein V, Saunier M, Joseph K, 
Caudroy S, Pretet JL, Birembaut P and Clavel C. 
HPV prevalence, viral load and physical state of 
HPV-16 in cervical smears of patients with dif-
ferent grades of CIN. Int J Cancer 2007; 121: 
2198-2204. 
[12] Cricca M, Morselli-Labate AM, Venturoli S, Am-
bretti S, Gentilomi GA, Gallinella G, Costa S, 
Musiani M and Zerbini M. Viral DNA load, physi-
cal status and E2/E6 ratio as markers to grade 
HPV16 positive women for high-grade cervical 
lesions. Gynecol Oncol 2007; 106: 549-557. 
[13] Swan DC, Tucker RA, Tortolero-Luna G, Mitchell 
MF, Wideroff L, Unger ER, Nisenbaum RA, 
Reeves WC and Icenogle JP. Human papillo-
mavirus (HPV) DNA copy number is dependent 
on grade of cervical disease and HPV type. J 
Clin Microbiol 1999; 37: 1030-1034. 
[14] Josefsson AM, Magnusson PK, Ylitalo N, Soren-
sen P, Qwarforth-Tubbin P, Andersen PK, Mel-
bye M, Adami HO and Gyllensten UB. Viral load 
of human papilloma virus 16 as a determinant 
for development of cervical carcinoma in situ: a 
nested case-control study. Lancet 2000; 355: 
2189-2193. 
[15] Ylitalo N, Sorensen P, Josefsson AM, Magnus-
son PK, Andersen PK, Ponten J, Adami HO, 
Gyllensten UB and Melbye M. Consistent high 
viral load of human papillomavirus 16 and risk 
of cervical carcinoma in situ: a nested case-
control study. Lancet 2000; 355: 2194-2198. 
[16] van Duin M, Snijders PJ, Schrijnemakers HF, 
Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van 
den Brule AJ, Verheijen RH, Helmerhorst TJ and 
Meijer CJ. Human papillomavirus 16 load in 
normal and abnormal cervical scrapes: an indi-
cator of CIN II/III and viral clearance. Int J Can-
cer 2002; 98: 590-595. 
[17] Boulet GA, Benoy IH, Depuydt CE, Horvath CA, 
Aerts M, Hens N, Vereecken AJ and Bogers JJ. 
Human papillomavirus 16 load and E2/E6 ratio 
in HPV16-positive women: biomarkers for cervi-
cal intraepithelial neoplasia >or=2 in a liquid-
based cytology setting? Cancer Epidemiol Bio-
markers Prev 2009; 18: 2992-2999. 
[18] Constandinou-Williams C, Collins SI, Roberts S, 
Young LS, Woodman CB and Murray PG. Is hu-
man papillomavirus viral load a clinically useful 
predictive marker? A longitudinal study. Cancer 
Epidemiol Biomarkers Prev 2010; 19: 832-
837. 
[19] Gravitt PE, Kovacic MB, Herrero R, Schiffman 
M, Bratti C, Hildesheim A, Morales J, Alfaro M, 
Sherman ME, Wacholder S, Rodriguez AC and 
Burk RD. High load for most high risk human 
papillomavirus genotypes is associated with 
prevalent cervical cancer precursors but only 
HPV16 load predicts the development of inci-
dent disease. Int J Cancer 2007; 121: 2787-
2793. 
[20] Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang 
C, Galloway DA, Koutsky LA, Kiviat NB and 
Schiffman M. Viral Load in the Natural History 
of Human Papillomavirus Type 16 Infection: A 
Nested Case-control Study. J Infect Dis 2011; 
203: 1425-1433. 
[21] Hesselink AT, Berkhof J, Heideman DA, 
Bulkmans NW, van Tellingen JE, Meijer CJ and 
Snijders PJ. High-risk human papillomavirus 
DNA load in a population-based cervical screen-
ing cohort in relation to the detection of high-
grade cervical intraepithelial neoplasia and 
cervical cancer. Int J Cancer 2009; 124: 381-
386. 
[22] Hudelist G, Manavi M, Pischinger KI, Watkins-
Riedel T, Singer CF, Kubista E and Czerwenka 
KF. Physical state and expression of HPV DNA 
in benign and dysplastic cervical tissue: differ-
ent levels of viral integration are correlated with 
lesion grade. Gynecol Oncol 2004; 92: 873-
880. 
[23] Li W, Wang W, Si M, Han L, Gao Q, Luo A, Li Y, 
Lu Y, Wang S and Ma D. The physical state of 
HPV16 infection and its clinical significance in 
cancer precursor lesion and cervical carci-
noma. J Cancer Res Clin Oncol 2008; 134: 
1355-1361. 
[24] Tonon SA, Picconi MA, Bos PD, Zinovich JB, 
Galuppo J, Alonio LV and Teyssie AR. Physical 
status of the E2 human papilloma virus 16 viral 
gene in cervical preneoplastic and neoplastic 
lesions. J Clin Virol 2001; 21: 129-134. 
[25] Cricca M, Venturoli S, Leo E, Costa S, Musiani 
M and Zerbini M. Molecular analysis of HPV 16 
E6I/E6II spliced mRNAs and correlation with 
the viral physical state and the grade of the 
cervical lesion. J Med Virol 2009; 81: 1276-
1282. 
[26] Kulmala SM, Syrjanen SM, Gyllensten UB, Sha-
balova IP, Petrovichev N, Tosi P, Syrjanen KJ 
and Johansson BC. Early integration of high 
Biomarkers of HPV16-positive women 
 
 
203                                                                                                            Am J Cancer Res 2012;2(2):192-203 
copy HPV16 detectable in women with normal 
and low grade cervical cytology and histology. J 
Clin Pathol 2006; 59: 513-517. 
[27] Collins SI, Constandinou-Williams C, Wen K, 
Young LS, Roberts S, Murray PG and Woodman 
CB. Disruption of the E2 gene is a common and 
early event in the natural history of cervical 
human papillomavirus infection: a longitudinal 
cohort study. Cancer Res 2009; 69: 3828-
3832. 
[28] Desaintes C, Demeret C, Goyat S, Yaniv M and 
Thierry F. Expression of the papillomavirus E2 
protein in HeLa cells leads to apoptosis. EMBO 
J 1997; 16: 504-514. 
[29] Stubenrauch F, Straub E, Fertey J and Iftner T. 
The E8 repression domain can replace the E2 
transactivation domain for growth inhibition of 
HeLa cells by papillomavirus E2 proteins. Int J 
Cancer 2007; 121: 2284-2292. 
[30] Gravitt PE, Peyton CL, Apple RJ and Wheeler 
CM. Genotyping of 27 human papillomavirus 
types by using L1 consensus PCR products by a 
single-hybridization, reverse line blot detection 
method. J Clin Microbiol 1998; 36: 3020-3027. 
[31] Kjaer S, Hogdall E, Frederiksen K, Munk C, van 
den Brule A, Svare E, Meijer C, Lorincz A and 
Iftner T. The absolute risk of cervical abnormali-
ties in high-risk human papillomavirus-positive, 
cytologically normal women over a 10-year 
period. Cancer Res 2006; 66: 10630-10636. 
[32] Kjaer SK, Breugelmans G, Munk C, Junge J, 
Watson M and Iftner T. Population-based preva-
lence, type- and age-specific distribution of HPV 
in women before introduction of an HPV-
vaccination program in Denmark. Int J Cancer 
2008; 123: 1864-1870. 
[33] Peitsaro P, Johansson B and Syrjanen S. Inte-
grated human papillomavirus type 16 is fre-
quently found in cervical cancer precursors as 
demonstrated by a novel quantitative real-time 
PCR technique. J Clin Microbiol 2002; 40: 886-
891. 
[34] Kalantari M, Karlsen F, Kristensen G, Holm R, 
Hagmar B and Johansson B. Disruption of the 
E1 and E2 reading frames of HPV 16 in cervical 
carcinoma is associated with poor prognosis. 
Int J Gynecol Pathol 1998; 17: 146-153. 
[35] Saunier M, Monnier-Benoit S, Mauny F, Dal-
stein V, Briolat J, Riethmuller D, Kantelip B, 
Schwarz E, Mougin C and Pretet JL. Analysis of 
human papillomavirus type 16 (HPV16) DNA 
load and physical state for identification of 
HPV16-infected women with high-grade lesions 
or cervical carcinoma. J Clin Microbiol 2008; 
46: 3678-3685. 
[36] Arias-Pulido H, Peyton CL, Joste NE, Vargas H 
and Wheeler CM. Human papillomavirus type 
16 integration in cervical carcinoma in situ and 
in invasive cervical cancer. J Clin Microbiol 
2006; 44: 1755-1762. 
[37] Gravitt PE, Burk RD, Lorincz A, Herrero R, Hilde-
sheim A, Sherman ME, Bratti MC, Rodriguez AC, 
Helzlsouer KJ and Schiffman M. A comparison 
between real-time polymerase chain reaction 
and hybrid capture 2 for human papillomavirus 
DNA quantitation. Cancer Epidemiol Bio-
markers Prev 2003; 12: 477-484. 
[38] Brandsma JL, Shlyankevich M, Zhang L, Slade 
MD, Goodwin EC, Peh W and Deisseroth AB. 
Vaccination of rabbits with an adenovirus vec-
tor expressing the papillomavirus E2 protein 
leads to clearance of papillomas and infection. 
J Virol 2004; 78: 116-123. 
[39] Nakagawa M, Stites DP, Patel S, Farhat S, Scott 
M, Hills NK, Palefsky JM and Moscicki AB. Per-
sistence of human papillomavirus type 16 in-
fection is associated with lack of cytotoxic T 
lymphocyte response to the E6 antigens. J In-
fect Dis 2000; 182: 595-598. 
[40] Lillo FB, Lodini S, Ferrari D, Stayton C, Taccagni 
G, Galli L, Lazzarin A and Uberti-Foppa C. Deter-
mination of human papillomavirus (HPV) load 
and type in high-grade cervical lesions surgi-
cally resected from HIV-infected women during 
follow-up of HPV infection. Clin Infect Dis 2005; 
40: 451-457. 
[41] Heard I, Tassie JM, Schmitz V, Mandelbrot L, 
Kazatchkine MD and Orth G. Increased risk of 
cervical disease among human immunodefi-
ciency virus-infected women with severe immu-
nosuppression and high human papillomavirus 
load(1). Obstet Gynecol 2000; 96: 403-409. 
[42] Nindl I, Greinke C, Zahm DM, Stockfleth E, 
Hoyer H and Schneider A. Human papillomavi-
rus distribution in cervical tissues of different 
morphology as determined by hybrid capture 
assay and PCR. Int J Gynecol Pathol 1997; 16: 
197-204. 
[43] McCrory DC, Matchar DB, Bastian L, Datta S, 
Hasselblad V, Hickey J, Myers E and Nanda K. 
Evaluation of cervical cytology. Evid Rep Tech-
nol Assess (Summ) 1999; 1-6. 
 
